Tag Archives: Amgen

Can Amgen bone drug Evenity make a comeback? FDA, analysts aren't so sure

Amgen osteoporosis candidate Evenity (romosozumab) is trying to score an approval after cardiovascular red flags derailed it in mid-2017. But analysts aren’t so optimistic. The drug is slated to go before an FDA panel of experts later this week, but briefing documents from the FDA suggest that “risk for approval remains high and even if… Read More »